Anonymous
Guest
Anonymous
Guest
$136M upfront to license elifibranor and $407M in potential additional milestones, I suppose it's better than the deal for palovarotene...but then that deal was an epic waste of money.
$136M upfront to license elifibranor and $407M in potential additional milestones, I suppose it's better than the deal for palovarotene...but then that deal was an epic waste of money.
just remember our CEO called this debacle a "hiccup" for palvo. Classic view on a colossal business fuck up